logo
logo

Intercure Continuing Its Medical Cannabis Consolidation Strategy, Announces Strategic Acquisition Of Cannomed Pharmacy Chain

Intercure Continuing Its Medical Cannabis Consolidation Strategy, Announces Strategic Acquisition Of Cannomed Pharmacy Chain

09/02/21, 1:41 PM
Industry
agriculture and farming
food and beverage
consumer goods
other
health care
community and lifestyle
InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it has signed an agreement in which InterCure will purchase strategic assets from Cannomed (TASE: CNMD), an Israel-based company and owner of a pharmacy chain specializing in dispensing medical cannabis.

Company Info

Company
InterCure (dba Canndoc)
Company info
InterCure (dba Canndoc) InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to maintain its position as Israel’s leading cannabis company as well as to drive further growth through global expansion. For more information, visit: http://www.intercure.co